Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27698188 | 0.88 | P2RY12 (0.46) | P2RY12SMN1; SMN2MAPTCYP2C9CYP2C19 | |
| Potassium Ion SCHEMBL4104778 | 0.87 | P2RY12 (0.45) | P2RY12SMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL4104705 | 0.85 | P2RY12 (0.49) | P2RY12SMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL5343437 | 0.78 | P2RY12 (0.79) | P2RY12CYP2C9CYP2C19 | |
| SCHEMBL2419355 | 0.78 | P2RY12 (0.62) | P2RY12MEN1KMT2A | |
| SCHEMBL3935766 | 0.76 | P2RY12 (0.63) | P2RY12 | |
| SCHEMBL4111253 | 0.74 | CXCR3 (0.49) | P2RY12LMNA | |
| SCHEMBL25030014 | 0.74 | MAPT (0.57) | SMN1; SMN2MAPTKDM4EMEN1KMT2A | |
| SCHEMBL4109651 | 0.74 | P2RY12 (0.56) | P2RY12SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5314024 | 0.73 | MAPT (0.54) | P2RY12SMN1; SMN2MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885SMN1; SMN2 3557/4885MAPT 3696/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885SMN1; SMN2 4121/4885MAPT 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.